Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
compounding
Pharma
Novo reports mixed sales on GLP-1 stalwarts Ozempic, Wegovy
After disappointing earnings from Lilly last week, Novo Nordisk’s report on the performance of its GLP-1s Ozempic and Wegovy is more of a mixed bag.
Fraiser Kansteiner
Nov 6, 2024 2:34pm
Lilly cuts revenue guidance as momentum stalls for tirzepatide
Oct 30, 2024 9:47am
Novo asks FDA to prevent compounders from making GLP-1 knockoffs
Oct 23, 2024 2:29pm
FDA reviews decision to put Lilly's tirzepatide on shortage list
Oct 14, 2024 11:20am
Minus one of its GLP-1 cash cows, compounding group sues FDA
Oct 8, 2024 10:52am
FDA removes Lilly's Mounjaro and Zepbound from its shortage list
Oct 3, 2024 11:22am
